Recent advances in treatment options, including immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi + MEKi), have contributed to a decline in melanoma-related mortality [5, 6]. The gene discussed is BRAF; the disease is melanoma.